Select Publication (2010-2017)

1. Papillon-Cavanagh S*, Lu C*, Gayden T, Mikael LG, Bechet D, Karamboulas C, Ailles L, Karamchandani J, Weinreb I, Goldstein D, Lewis PW, Dancu O, Dhaliwal S, Stecho W, Howlett CJ, Mymryk JS, Barrett JW, Nichols AC, Allis CD, Majewski J, Jabado N. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet 2017 49: 180-185. (* equal contribution) [Pubmed]

- Featured in Radio Canada International

2. Weinberg DN, Allis CD**, Lu C**.  Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb Perspect Med 2017 7: pii: a026443. (** co-corresponding) [Pubmed]

3. Bayliss J*, Mukherjee P*, Lu C*, Jain SU, Chung C, Martinez D, Sabari B, Margol AS, Panwalkar P, Parolia A, Pekmezci M, McEachin RC, Cieslik M, Tamrazi B, Garcia BA, La Rocca G, Santi M, Lewis PW, Melnik A, Allis CD, Thompson CB, Chinnaiyan AM, Judkins AR, Venneti S.  Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 2016 8: 366ra161. (* equal contribution) [Pubmed]

-Highlighted in Cancer Research and Neurosurgery

4. Lu C, Jain SU, Hoelper D, Bechet D, Molden RC, Ran L, Murphy D, Venneti S, Hameed M, Pawel BR, Wunder J, Dickson BC, Lundgren SM, Jani KS, De Jay N, Papillon-Cavanagh S, Andrulis IL, Sawyer SL, Grynspan D, Turcotte RE, Nadaf J, Fahiminiyah S, Muir TW, Majewski J, Thompson CB, Chi P, Garcia BA, Allis CD, Jabado N, Lewis PW. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 2016 352: 844-9. [Pubmed]

- Highlighted in Nat Rev Cancer, Nat Rev Genetics, Cancer Discov; Recommended by F1000

5. Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. Induction of sarcomas by mutant IDH2. Genes Dev 2013 27: 1986-98. [Pubmed]

- Highlighted in Nat Rev Cancer

6. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012 16: 9-17. [Pubmed]

7. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012 483: 474–78. [Pubmed

- Highlighted in Nature News, Cell Res, Sci Signal, Nat Rev Cancer and Cancer Res; Recommended by F1000

8. Figueroa ME*, Abdel-Wahab O*, Lu C*, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 18: 553-67. (* equal contribution) [Pubmed]

- Recommended by F1000